Monthly information on share capital and company voting rights

Rhea-AI Summary

Cellectis announced its commitment to advancing CAR-T immunotherapies, focusing on off-the-shelf gene-edited T-cells for cancer treatment. As of August 31, 2020, the company has 42,486,133 shares outstanding and 47,940,778 voting rights. Their innovative approach leverages TALEN® technology to target a range of cancers including AML, B-ALL, and MM. Headquartered in Paris, Cellectis is publicly traded on both Nasdaq (CLLS) and Euronext Growth (ALCLS). The company aims to meet urgent medical needs in oncology, leveraging over 20 years of gene editing expertise.

Positive

• Development of off-the-shelf CAR-T immunotherapies may result in significant market differentiation.
• Utilization of TALEN® gene-editing technology showcases innovation in cancer treatment.
• Focus on multiple high-need cancers (AML, B-ALL, MM) indicates broad market potential.

Negative

• None.

(Article 223-16 of General Regulation of the French financial markets authority)

NEW YORK, Sept. 07, 2020 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date	Total number of shares in the capital	Total number of voting  rights
08/31/2020	42,486,133	47,940,778

About Cellectis
Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 20 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN^®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.

As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM).

Cellectis headquarters are in Paris, France, with additional locations in New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). For more information, visit www.cellectis.com.

Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

TALEN^® is a registered trademark owned by Cellectis.

For further information, please contact:

Media contacts:
Jennifer Moore, VP, Communications, 917-580-1088, media@cellectis.com
Caitlin Kasunich, KCSA Strategic Communications, 212-896-1241, ckasunich@kcsa.com

IR contact:
Simon Harnest, VP, Corporate Strategy and Finance, 646-385-9008, simon.harnest@cellectis.com 

PDF available at: http://ml.globenewswire.com/Resource/Download/cb80f5e7-e4fa-458c-862b-575f7ec63538

 

 

FAQ

What recent developments has Cellectis made in CAR-T immunotherapies?

Cellectis is advancing the development of off-the-shelf, gene-edited CAR-T cells aimed at treating cancer.

What is the stock ticker for Cellectis?

Cellectis is listed on Nasdaq under the ticker symbol CLLS.

How many shares are outstanding for Cellectis as of August 31, 2020?

As of August 31, 2020, Cellectis has 42,486,133 shares outstanding.

What types of cancer is Cellectis targeting?

Cellectis is targeting acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL), and multiple myeloma (MM).

Where is Cellectis headquartered?

Cellectis is headquartered in Paris, France, with additional locations in New York and Raleigh, North Carolina.